A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
Por:
Marin, IGGY, Hernandez-Sanchez, M, Rodriguez-Vicente, AE, Sanzo, C, Aventin, A, Puiggros, A, Collado, R, Heras, C, Munoz, C, Delgado, J, Ortega, M, Gonzalez, MT, Marugan, I, de la Fuente, I, Recio, I, Bosch, F, Espinet, B, Gonzalez, M, Hernandez-Rivas, JM, Hernandez, JA
Publicada:
1 jun 2016
Resumen:
The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in 60% of cells, with a median TTFT of 49months (CI95%, 39-58) vs 30months (CI95%, 22-38) (P=0.001); and a median OS of 159months (CI95%, 119-182), vs 96months (CI95%, 58-134) (P=0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q-, high (2)microglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in 60% of cells, high lymphocyte count, B symptoms, and 11q- in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high (2)microglobulin, 11q-, and CD38. In the multivariate analysis, only Binet stage, 11q-, and high 2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcome. Copyright (c) 2015 John Wiley & Sons, Ltd.
Filiaciones:
Marin, IGGY:
Hosp Univ Infanta Leonor, Serv Hematol, Madrid, Spain
Hernandez-Sanchez, M:
IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain
Univ Salamanca USAL CSIC, Ctr Invest Canc IBMCC, Salamanca, Spain
Rodriguez-Vicente, AE:
IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain
Univ Salamanca USAL CSIC, Ctr Invest Canc IBMCC, Salamanca, Spain
Sanzo, C:
Hosp Cent Asturias, Oviedo, Spain
Aventin, A:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Puiggros, A:
Hosp del Mar, Barcelona, Spain
Collado, R:
Gen Hosp, Valencia, Spain
Heras, C:
Hosp Univ Infanta Leonor, Serv Hematol, Madrid, Spain
Munoz, C:
Hosp Univ Infanta Leonor, Serv Hematol, Madrid, Spain
Delgado, J:
Hosp Clin Barcelona, Barcelona, Spain
Ortega, M:
Hosp Valle De Hebron, Barcelona, Spain
Gonzalez, MT:
Fdn Publ Galega Med Xenom, Santiago De Compostela, Spain
Marugan, I:
Hosp Clin Univ, Valencia, Spain
de la Fuente, I:
Hosp Rio Hortega, Valladolid, Spain
Recio, I:
Hosp Nuestra Senora de Sonsoles, Avila, Spain
Bosch, F:
Hosp Valle De Hebron, Barcelona, Spain
Espinet, B:
Hosp del Mar, Barcelona, Spain
Gonzalez, M:
IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain
Univ Salamanca USAL CSIC, Ctr Invest Canc IBMCC, Salamanca, Spain
Fdn Publ Galega Med Xenom, Santiago De Compostela, Spain
Hernandez-Rivas, JM:
IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain
Univ Salamanca USAL CSIC, Ctr Invest Canc IBMCC, Salamanca, Spain
Hernandez, JA:
Hosp Univ Infanta Leonor, Serv Hematol, Madrid, Spain
Univ Complutense, Madrid, Spain
Green Accepted
|